--- title: "Kyntra Bio gets Nasdaq delisting determination" url: "https://aibio.space/news/kyntra-bio-gets-nasdaq-delisting-determination-requests-hearing/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-06" section: "Listings" tickers: "NASDAQ:KYNB" source: "https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/kynb-20260930.htm" summary: "Nasdaq staff said Kyntra Bio had not shown compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. A hearing request keeps the stock tradi" --- By the aibio.space news desk. Sources - [Kyntra Bio, Inc. 8-K (2026-10-06)](https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/kynb-20260930.htm) [KYNB](https://aibio.space/companies/kyntra-bio/) 2026-10-06 # Kyntra Bio gets Nasdaq delisting determination, requests a hearing Tickers [KYNB](https://aibio.space/companies/kyntra-bio/) Nasdaq staff said Kyntra Bio had not shown compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. A hearing request keeps the stock trading for now. ## Key facts - **Company**: Kyntra Bio, Inc. (NASDAQ: KYNB) - **News type**: Listings - **Primary source**: [Kyntra Bio, Inc. 8-K (2026-10-06)](https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/kynb-20260930.htm) *The Washington Monument and the city beyond. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* ## The determination Kyntra Bio, Inc. (Nasdaq: [KYNB](https://aibio.space/companies/kyntra-bio/)) received a determination letter on September 30, 2026 from the Listing Qualifications Staff of the Nasdaq Stock Market LLC. The letter said the company had not yet demonstrated compliance with Nasdaq Listing Rule 5450(b) as of a September 29, 2026 deadline, and that the Staff had therefore decided to delist its common stock from the Nasdaq Global Select Market. The company reported the letter in a Form 8-K signed on October 6, 2026 by General Counsel John Alden. Kyntra Bio said it has timely requested a hearing before a Nasdaq Hearings Panel to review the Staff's decision and to seek additional time to regain compliance. The request stays the suspension of the company's securities and the filing of a Form 25-NSE until the Panel issues a written decision. An extension could run up to 180 days from the Staff's determination under Listing Rule 5815(c)(1)(A). Until the Panel decides, the stock remains listed and continues to trade on the Global Select Market under the symbol KYNB. ## How the company got here The problem dates to April 2, 2026, when Nasdaq's Staff told Kyntra Bio it was not in compliance with Listing Rule 5450(b)(3)(A). That rule requires total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. The company also did not satisfy the alternative stockholders' equity or market value of listed securities standards under Rule 5450(b). The 8-K gives no figures for any of those tests, and it does not say how long the company had to cure the shortfall before the September 29 deadline passed. ## What the annual figures show The company's annual report for 2025, filed March 16, 2026, shows why the revenue test is hard to meet. Revenue was $6.4 million in 2025, down from $29.6 million in 2024, against a floor of $50 million. Research and development expense fell from $95.7 million in 2024 to $23.5 million in 2025. Cash used in operations fell from $138.0 million to $4.8 million over the same two years. The bottom line moved the other way. Kyntra Bio reported net income of $183.5 million for 2025, after a net loss of $47.6 million for 2024. The figures given here do not say what produced the profit. The annual report's forward-looking statements refer to the closing of the sale of the company's roxadustat business in China, but they do not link the profit to that sale. Revenue, research spending and cash used in operations all fell over the same period. Cash and cash equivalents were $47.9 million at the end of 2025, compared with $50.5 million at the end of 2024. Short-term investments were $41.1 million at the end of 2025, with none a year earlier. At June 30, 2026, the company held $50.6 million in cash and cash equivalents and $40.7 million in short-term investments. The figures provided do not include total assets or stockholders' equity, so they do not show how far short Kyntra Bio falls on the other two Nasdaq standards. ## What happens next The company says it is actively preparing a compliance plan for the Panel. It also cautions that there can be no assurance the Panel will grant its request for continued listing, or that it will be able to regain compliance with the continued listing requirements within any extension period the Panel allows. The 8-K does not give a hearing date and does not describe what the compliance plan contains. The outcome rests with the Panel. If it grants an extension, the longest period the 8-K cites is 180 days from the Staff's September 30 determination. The stay on the suspension and on the Form 25-NSE filing lasts only until the Panel issues its written decision. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story KYNB Kyntra Bio, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/kyntra-bio-gets-nasdaq-delisting-determination-requests-hearing/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kyntra Bio gets Nasdaq delisting determination", 2026-10-06, https://aibio.space/news/kyntra-bio-gets-nasdaq-delisting-determination-requests-hearing/